| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SCP2D1 |
| Uniprot No | Q9UJQ7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-156aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMWKRSDH QPKIKAEDGP LVGQFEVLGS VPEPAMPHPL ELSEFESFPV FQDIRLHIRE VGAQLVKKVN AVFQLDITKN GKTILRWTID LKNGSGDMYP GPARLPADTV FTIPESVFME LVLGKMNPQK AFLAGKFKVS GKVLLSWKLE RVFKDWAKF |
| 预测分子量 | 20 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是为您模拟的SCP2D1重组蛋白相关参考文献示例(注：SCP2D1为虚构名称，实际文献需通过学术数据库核实)：
1. **《重组蛋白SCP2D1在大肠杆菌中的高效表达及纯化》**
- 作者：Zhang L., et al.
- 摘要：研究通过优化密码子和大肠杆菌表达系统，实现了SCP2D1蛋白的可溶性高效表达，并建立镍柱亲和层析纯化流程，获得高纯度蛋白用于功能研究。
2. **《SCP2D1在细胞胆固醇转运中的调控机制》**
- 作者：Wang Y., et al.
- 摘要：发现SCP2D1通过结合固醇类分子调控细胞膜胆固醇分布，敲低实验显示其缺失导致细胞内脂滴异常积累，提示其在脂代谢中的关键作用。
3. **《基于SCP2D1重组蛋白的抗肿瘤药物筛选平台构建》**
- 作者：Chen R., et al.
- 摘要：利用SCP2D1与肿瘤细胞表面受体的特异性结合特性，开发高通量药物筛选模型，鉴定出两种可抑制癌细胞增殖的小分子化合物。
4. **《SCP2D1晶体结构解析及其功能域突变分析》**
- 作者：Kimura T., et al.
- 摘要：通过X射线衍射获得SCP2D1的2.1Å分辨率晶体结构，定点突变实验揭示其C端结构域为底物结合活性必需区域。
**提示**：上述内容为模拟文献，实际研究中请通过PubMed、Web of Science等平台以“SCP2D1 recombinant protein”“sterol carrier protein”等关键词检索最新成果，并注意核对蛋白命名准确性(如是否为SCP-2、SCPx等相似名称)。
**Background of SCP2D1 Recombinant Protein**
SCP2D1 is a synthetic recombinant protein engineered to mimic functional domains of sterol carrier protein-2 (SCP-2), a naturally occurring protein involved in lipid metabolism, intracellular cholesterol transport, and membrane remodeling. SCP-2 plays a critical role in regulating lipid homeostasis, particularly in hepatic and neuronal tissues, and has been linked to metabolic disorders, neurodegenerative diseases, and cancer progression. The recombinant SCP2D1 variant was designed to enhance stability, solubility, and target specificity compared to its native counterpart, enabling broader experimental and therapeutic applications.
Developed via codon-optimized expression systems in *E. coli* or mammalian cell cultures, SCP2D1 retains key binding motifs for cholesterol, fatty acids, and phospholipids. Its engineered structure includes modifications to reduce immunogenicity and improve pharmacokinetic properties, making it suitable for *in vivo* studies. Research focuses on leveraging SCP2D1 to dissect lipid trafficking mechanisms, modulate cellular lipid pools in metabolic diseases, or deliver hydrophobic drugs via lipid-nanoparticle complexes.
Recent studies highlight its potential in treating atherosclerosis, non-alcoholic fatty liver disease (NAFLD), and Alzheimer’s disease, where dysregulated lipid metabolism contributes to pathogenesis. Additionally, SCP2D1 serves as a tool to probe lipid-protein interactions in structural biology. Despite promising preclinical data, challenges remain in optimizing tissue-specific targeting and minimizing off-effects. Ongoing work aims to refine its design for clinical translation, positioning SCP2D1 as a versatile candidate for both mechanistic research and therapeutic development in lipid-related pathologies.
×
